Renal Cell Carcinoma
Advertisement
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
Dr. Goswami discusses the trials that are changing our understanding of resistance to ICIs in kidney and bladder cancer.
Patients with accRCC were assigned to receive either a conventional continuation strategy or a drug-free interval strategy.
In the final segment of a debate series, Brian Rini, MD, and Monty Pal, MD, debate RCC adjuvant therapeutic options.
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
The panel discusses triplet combinations in development for RCC.
The panel discusses the disappointing results of the COSMIC-313 trial.
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
The panel shares how they treat frontline papillary kidney cancer.
In the second segment of a debate series, Drs. Rini and Pal address kidney cancer clinical trials of interest.
The panel discusses treatment-related toxicities and when to consider stopping treatment.
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
In a debate series between Brian Rini, MD, and Monty Pal, MD, they discuss frontline RCC treatment options.
A review of adjuvant therapies shows patient characteristics that may result in favorable treatment responses.
Plasma and urine free glycosaminoglycan profiles—or GAGomes—can potentially be used as metabolic biomarkers for mRCC.
The panel compares three treatment regimens.
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
The panel discusses the CheckMate 8Y8 clinical trial.
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
Dr. Msaouel provides an overview of the molecular characteristics and treatment for nccRCC, with a particular focus on RMC.
Advertisement
670 Madison Ave.
Manalapan, NJ 07726